Grace Therapeutics presents corporate strategy for GTx-104 and GTx-102 programs

Grace Therapeutics released a June 2026 corporate presentation outlining its drug development pipeline and regulatory strategy. The company is pursuing FDA approval for GTx-104 for aneurysmal subarachnoid hemorrhage treatment and advancing GTx-102 for Ataxia Telangiectasia, with near-term regulatory meetings expected to clarify development pathways.